Patent SG-11201907272Y-A (SG)
Title: Alphavirus nsp mutants as vaccines
Inventor: NG LISA FONG POH
IPC: C07K14/18
Filed: 2018-02-07
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIP0 1 PCT olimion °nolo DID mo IV moilloinio oimIE (10) International Publication Number WO 2018/147802 Al (51) International Patent Classification: C07K 14/18 (2006.01) A61P 31/14 (2006.01) A61K 39/12 (2006.01) (21) International Application Number: PCT/SG2018/050052 (22) International Filing Date: 07 February 2018 (07.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201700950R 07 February 2017 (07.02.2017) SG (71) Applicants: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis, Singapore 138632 (SG). UNIVERSITY OF TARTU [EE/EE]; Ulikooli str. '18, 50090 Iartu (EE). (72) Inventors: NG, Lisa Fong Poh; c/o Singapore Immunol- ogy Network, 8A Biomedical Grove, Singapore 138648 (SG). CHAN, Yi Hao; c/o Singapore Immunology Net- work, 8A Biomedical Grove, Singapore 138648 (SG). MERITS, Andres; Institute of Technology, University of Tartu, Nooruse 1, Iartu 50411 (EE). UTT, Age; Institute of Technology, University of Tartu, Nooruse 1, Iartu 50411 (EE). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE 1-1 N O GC N 1-1 00 O 1-1 N C (54) Title: ALPHAVIRUS NSP MUTANTS AS VACCINES (57) : The present invention generally relates to a recombinant polypeptides comprising an amino acid sequence, or a variant thereof derived from the Chikungunya virus non-structural polyprotein (SEQ ID NO: 1) comprising one or more mutations selected from the group consisting of (a) a mutation at a position equivalent to amino acid position 532 of SEQ ID NO: 1, and (b) a mutation at a position equivalent at amino acid position 1050 of SEQ ID NO: 1. Also claimed are polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses comprising said polypeptides. The present disclosure also relates to methods for eliciting an immune response against alphavirus infection using the immunogenic compositions of alphaviruses mutants described herein.